TW202321216A - 晶形 - Google Patents

晶形 Download PDF

Info

Publication number
TW202321216A
TW202321216A TW111128732A TW111128732A TW202321216A TW 202321216 A TW202321216 A TW 202321216A TW 111128732 A TW111128732 A TW 111128732A TW 111128732 A TW111128732 A TW 111128732A TW 202321216 A TW202321216 A TW 202321216A
Authority
TW
Taiwan
Prior art keywords
piperidin
dimethyl
oxo
piperidine
oxindolin
Prior art date
Application number
TW111128732A
Other languages
English (en)
Chinese (zh)
Inventor
青山英幸
沼田豊治
須藤正樹
岩田康弘
Original Assignee
日商拉夸里亞創藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商拉夸里亞創藥股份有限公司 filed Critical 日商拉夸里亞創藥股份有限公司
Publication of TW202321216A publication Critical patent/TW202321216A/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW111128732A 2021-07-30 2022-08-01 晶形 TW202321216A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163227692P 2021-07-30 2021-07-30
US63/227,692 2021-07-30

Publications (1)

Publication Number Publication Date
TW202321216A true TW202321216A (zh) 2023-06-01

Family

ID=85087024

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111128732A TW202321216A (zh) 2021-07-30 2022-08-01 晶形

Country Status (7)

Country Link
EP (1) EP4377309A1 (fr)
KR (1) KR20240042400A (fr)
CN (1) CN117616022A (fr)
BR (1) BR112023025271A2 (fr)
CA (1) CA3223173A1 (fr)
TW (1) TW202321216A (fr)
WO (1) WO2023008585A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547415T3 (es) * 2009-02-27 2015-10-06 Raqualia Pharma Inc Derivados de oxiindol con actividad agonista del receptor de motilina

Also Published As

Publication number Publication date
BR112023025271A2 (pt) 2024-02-27
EP4377309A1 (fr) 2024-06-05
CA3223173A1 (fr) 2023-02-02
KR20240042400A (ko) 2024-04-02
WO2023008585A1 (fr) 2023-02-02
CN117616022A (zh) 2024-02-27

Similar Documents

Publication Publication Date Title
CA2836372C (fr) Forme polymorphe de l'acide 4-{[4-({[4-(2,2,2-trifluoroethoxy)- 1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h- pyran-4-carboxylique
TWI610929B (zh) 多形體形式
TW202321216A (zh) 晶形
RU2679619C2 (ru) Солевое производное бензизоксазола
CA2910123C (fr) Polymorphe de 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide de l-tartrate